Quantcast

Latest Alzheimer's disease clinical research Stories

2014-09-15 08:29:32

- Significantly Improved Agitation in 220-Patient 10-week Study - ALISO VIEJO, Calif., Sept. 15, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. Treatment with AVP-923 was associated with significantly reduced agitation as measured by the primary endpoint, the agitation/aggression...

2014-07-16 16:24:01

ABERDEEN, Scotland and SINGAPORE, July 16, 2014 /PRNewswire/ -- TauRx Therapeutics Ltd [http://www.taurx.com ] announced it has achieved its target enrollment of 833 subjects into one of its two ongoing multi-center Phase III clinical trials of LMTX(TM) [http://taurx.com/lmtx-for-ad ], a tau aggregation inhibitor, for the treatment of Alzheimer's Disease [AD]. This placebo-controlled clinical trial (Protocol TRx-237-015 [http://taurx.com/015-clinical-study.html ]) has...

2014-07-15 04:22:22

ABERDEEN, Scotland and SINGAPORE, July 15, 2014 /PRNewswire/ -- TauRx Therapeutics Ltd [http://www.taurx.com ] today announced it has achieved its target enrolment of 833 subjects into one of its two ongoing multi-centre Phase III clinical trials of LMTX(TM) [http://taurx.com/lmtx-for-ad ], a tau aggregation inhibitor, for the treatment of Alzheimer's Disease [AD]. This placebo-controlled clinical trial (Protocol TRx-237-015 [http://taurx.com/015-clinical-study.html ]) has...

2014-07-15 04:22:13

Study Results Presented at the Alzheimer's Association International Conference 2014 INDIANAPOLIS, July 15, 2014 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE:LLY) announced results from an analyses of five datasets evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease in the natural course of the disease. Analysis findings demonstrate that cognitive deficits predict subsequent functional deficits and suggest that...

2014-07-13 12:20:48

Study Results Presented at the Alzheimer's Association International Conference 2014 INDIANAPOLIS, July 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376). Data results found that combination therapy was more effective in removing clumps of amyloid-beta protein...

2014-05-23 08:24:08

BOSTON, Mass., May 23, 2014 /PRNewswire/ -- AZTherapies, Inc. a company developing novel treatments for Alzheimer's disease based on technology licensed from Massachusetts General Hospital, announced that it has received notice from FDA that it may proceed with the Phase III clinical study submitted in its IND application. This study is for its lead program, ALZT-OP1, a novel combination therapy for the prevention and treatment of early Alzheimer's disease. ALZT-OP1 is a...

2014-04-14 12:32:55

Researchers recruiting patients with mild to moderate Alzheimer's disease to participate in six week study SUN CITY, Ariz., April 14, 2014 /PRNewswire/ -- Banner Sun Health Research Institute is proud to announce it is one of just five facilities in the United States to launch a new clinical trial for patients with mild to moderate Alzheimer's disease (AD). This study, titled "Effect of NeuroAD(TM), Combined TMS Stimulation and Cognitive Training, on the cognitive function of mild to...

Researchers Quantify Brain Protein Changes In Alzheimer Patients
2013-06-13 08:30:44

April Flowers for redOrbit.com - Your Universe Online A significant and potentially pivotal difference between the brains of patients with an inherited form of Alzheimer's disease and healthy family members who do not have it has been measured by researchers at Washington University School of Medicine in St. Louis. Researchers have long known that a protein fragment called amyloid beta builds up into plaques in Alzheimer´s patient´s brains. The theory is that these plaques...

2013-05-15 23:03:02

MetLife Foundation today announced the recipients of its 2013 Awards for Medical Research in Alzheimer´s Disease: Yueming Li, Ph.D., member and professor, Sloan-Kettering Institute and director and professor, Graduate Program in Pharmacology, Weill Medical College of Cornell University, and Lennart Mucke, M.D., director, Gladstone Institute of Neurological Disease, Joseph B. Martin Distinguished Professor of Neuroscience and professor of Neurology, University of California, San...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related